Edrophonium

From Self-sufficiency
Revision as of 07:14, 11 May 2010 by 131.211.165.252 (Talk) (Clinical uses)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Edrophonium
200px
Systematic (IUPAC) name
N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium
Identifiers
CAS Number 116-38-1
ATC code none
PubChem CID 8307
DrugBank APRD00944
ChemSpider 8006
Chemical data
Formula C10H16NOScript error: No such module "String".
Molar mass 166.24 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Edrophonium is a readily reversible acetylcholinesterase inhibitor. It prevents breakdown of the neurotransmitter acetylcholine and acts by competitively inhibiting the enzyme acetylcholinesterase, mainly at the neuromuscular junction. It is sold under the trade names Tensilon, Enlon and Reversol.

Clinical uses

Indication: PSVT refractory to vagal maneuvers; considered a second-line agent to Verapamil or Adenosine. Because its duration of action is only about 20 minutes, edrophonium (by the so-called Tensilon test) is used to differentiate myasthenia gravis from cholinergic crisis. In myasthenia gravis, where a person is not able to produce enough neuromuscular stimulation, edrophonium will reduce the muscle weakness by effectively supplying more acetylcholine. In a cholinergic crisis, where a person has too much neuromuscular stimulation, edrophonium will make the muscle weakness worse by inducing a depolarizing block.

Sources

  1. Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
  2. Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
es:Edrofonio

fr:Tensilon pt:Edrofônio